Electrostatic CTC Deactivation via Positive Field
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, such as radiotherapy, often result in side effects and are ineffective in selectively destroying circulating tumor cells (CTCs) without harming healthy cells.
Innovation Solution
The application of a positive electrostatic field to the bloodstream using an electrically conductive element with accumulated positive charges, which selectively deactivates or destroys CTCs by inducing internal apoptosis, while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiotherapy is applied to treat cancer, then tumor growth suppression is improved, but side effects on healthy tissues worsen
Solution Approach 1:
The patent applies local quality by differentiating the treatment approach for different cell types. The electrostatic field treatment specifically targets CTCs based on their unique surface charge properties, while normal cells are spared. This selective targeting achieves tumor suppression without the widespread side effects of conventional radiotherapy on healthy tissues.
Solution Approach 2:
The patent replaces the mechanical/physical radiation system with an electrostatic field-based system. Instead of using ionizing radiation that indiscriminately damages DNA in all cells, the invention uses electrostatic forces to selectively interact with and deactivate CTCs based on their surface charge characteristics, thereby eliminating side effects on healthy tissues.
2Measurement precision
If conventional methods are used to isolate and enumerate CTCs, then detection capability is improved, but the ability to destroy CTCs without affecting healthy cells worsens
Solution Approach 1:
The patent extracts the harmful aspect of conventional CTC targeting methods by eliminating the need for physical isolation and manual destruction. Instead of capturing and destroying individual CTCs through complex isolation procedures that risk affecting healthy cells, the invention applies an electrostatic field that selectively deactivates CTCs in their natural circulation, extracting the destruction function while removing the harmful side effects.
Solution Approach 2:
The patent substitutes mechanical isolation and destruction methods with an electrostatic field-based system. The electrostatic field penetrates the bloodstream and selectively interacts with CTCs based on their surface charge properties, achieving destruction without the mechanical complexity and collateral damage of conventional isolation methods.
3Object-affected harmful factors
If low energy stimulation is used for cancer treatment, then safety and reduced side effects are improved, but treatment effectiveness worsens
Solution Approach 1:
The patent applies parameter changes by optimizing the electrostatic field strength and duration parameters to achieve effective CTC deactivation using low energy. By carefully controlling these parameters, the treatment becomes sufficiently effective to impact tumor progression while maintaining safety and reducing side effects compared to high energy conventional therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively reduces the viability and destroys CTCs, inhibiting tumor growth and metastasis without causing side effects to healthy tissues, thus offering a safer and more targeted cancer treatment.
Implementation Method 1
accumulating positive electrostatic charges on an electrically conductive element by applying a positive electrostatic voltage... utilizing an electrostatic charge generator
Implementation Method 2
deactivating CTCs by applying a positive electrostatic field to bloodstream... inducing internal apoptosis in malignant tumors by positive electrostatic charges
Data Source
AI summary
A method for deactivating deactivating circulating cancer cells (CTCs). The method includes reducing viability of CTCs and/or destroying CTCs by applying a positive electrostatic field to bloodstream of a cancer patient.